Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

My initial Rolontis calculation of $350M/yr is accurate assuming 10% of the market. First, Neulasta 3rd Q US sales was $619M so if Rolontis took 10%, that equals $248M/yr for Rolontis not $215M. That's just a simple calculation error on my part. And secondly, the $619M of Neulasta 3rd Q US sales does not represent 100% of the market anymore, its really ~65% w biosims representing the rest. I think 10% of Neulasta 3rd Q sales ($619) is a little conservative since the market is already carved out some. I would bump up Rolontis sales to 15% of Neulasta's sales since it's already a carved out market. If you calculate 15% of the carved out $619/Qtr Neulasta sales that comes out to $371M/yr for Rolontis. Anyhows, this calculation will change by the end of the day since Amgen will be reporting quarterly earnings sometime today but anyway you look at it Rolontis will be a moneymaker just a question of how much.